Read this company snapshot
Daily valuation snapshot
Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares: source evidence dated 2026-10-09.
- Daily close (USD)
- $1.9
- Market capitalization (USD)
- $124,374.95
- Price / earnings (TTM)
- Not reported
- Price / book
- 0.02
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research CANF in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research CANF in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing CANF with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $1.9 |
| Market capitalization (USD) | $124,374.95 |
| Price / earnings (TTM) | Not reported |
| Price / book | 0.02 |
No matching rows. Clear the filter to see all records.
Read CANF's valuation metrics
Company size
Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares's recorded market capitalization is $124,374.95. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
CANF's recorded price-to-book ratio is 0.02. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares with Aurora
Use the snapshot above to ask a specific question about CANF. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow CANF's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.